Unicycive Therapeutics (UNCY) announced that data from the Company’s oxylanthanum carbonate, OLC, bioequivalence study in healthy volunteers was published in the peer-reviewed journal, Clinical Therapeutics. The publication, entitled, “Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate” described the study that established pharmacodynamic bioequivalence of OLC to Fosrenol. In the study, OLC was well tolerated and demonstrated bioequivalence to lanthanum carbonate.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics price target raised to $4 from $2.50 at H.C. Wainwright
- Unicycive Therapeutics files $100M mixed securities shelf
- Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
- Unicycive Therapeutics expects cash to fund operations into 2026
- Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue